Page last updated: 2024-12-10

sb 203186

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID3272300
CHEMBL ID1255781
CHEBI ID92477
SCHEMBL ID1041116
MeSH IDM0234983
PubMed CID9926639
CHEMBL ID1256727
MeSH IDM0234983

Synonyms (62)

Synonym
2-piperidin-1-ylethyl 1h-indole-3-carboxylate
BRD-K27141178-001-01-0
gtpl255
LOPAC0_000347
BPBIO1_000617
NCGC00015921-01 ,
NCGC00024790-01
tocris-0785
lopac-s-0443
BIOMOL-NT_000150
NCGC00024790-03
NCGC00024790-02
sb 203186
L005299
sb-203186
CHEMBL1255781
CCG-204442
bdbm85778
cas_135938-17-9
NCGC00015921-04
NCGC00015921-03
NCGC00015921-02
SCHEMBL1041116
2-(1-piperidyl)ethyl 1h-indole-3-carboxylate
2-(1-piperidyl)ethyl 1 h-indole-3-carboxylate
YGKPIROTKVQCCU-UHFFFAOYSA-N
CHEBI:92477
(1-piperidinyl)ethyl 1h-indole 3-carboxylate
1h-indole-3-carboxylic acid 2-piperidin-1-yl-ethyl ester
2-(piperidin-1-yl)ethyl 1h-indole-3-carboxylate ,
Q27088698
BRD-K27141178-003-02-4
EX-A7791
MLS002153377
smr001230766
1-piperidinylethyl-1h-indole-3-carboxylate hydrochloride
EU-0100347 ,
NCGC00093784-01
S 0443
CHEMBL1256727
sb203186
207572-69-8
2-(piperidin-1-yl)ethyl 1h-indole-3-carboxylate hydrochloride ,
135938-17-9
sb 203186 hydrochloride
AKOS024458649
2-piperidin-1-ylethyl 1h-indole-3-carboxylate;hydrochloride
J-006785
SR-01000075810-3
sr-01000075810
SR-01000075810-1
piperidin-1-ylethyl 1h-indole-3-carboxylate hcl
1h-indole-3-carboxylic acid, 2-(1-piperidinyl)ethyl ester, hydrochloride (1:1)
BS-45850
E78034
sb-203186 (hydrochloride)
sb203186 hydrochloride;sb 203186 hydrochloride
sb 203186 hcl
HY-101222
CS-0021007
2-(piperidin-1-yl)ethyl1h-indole-3-carboxylatehydrochloride
EX-A7791A
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
indolyl carboxylic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ThrombopoietinHomo sapiens (human)Potency10.00000.02517.304831.6228AID917; AID918
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency3.98110.001318.074339.8107AID926
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency3.98110.00207.533739.8107AID891
cytochrome P450 2C9 precursorHomo sapiens (human)Potency1.99530.00636.904339.8107AID883
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency16.81590.00106.000935.4813AID943; AID944
lethal factor (plasmid)Bacillus anthracis str. A2012Potency3.98110.020010.786931.6228AID912
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency1.99530.00638.235039.8107AID883
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.23780.003245.467312,589.2998AID2517
ATAD5 protein, partialHomo sapiens (human)Potency8.91250.004110.890331.5287AID504467
thioredoxin glutathione reductaseSchistosoma mansoniPotency22.38720.100022.9075100.0000AID485364
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.02240.035520.977089.1251AID504332
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency4.256223.934123.934123.9341AID1967
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency19.95260.01789.637444.6684AID588834
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID6194In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID624238Antagonists at Human 5-Hydroxytryptamine receptor 5-HT42001Naunyn-Schmiedeberg's archives of pharmacology, Feb, Volume: 363, Issue:2
5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle.
AID1346953Human 5-HT4 receptor (5-Hydroxytryptamine receptors)2001Naunyn-Schmiedeberg's archives of pharmacology, Feb, Volume: 363, Issue:2
5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (8.33)18.2507
2000's4 (33.33)29.6817
2010's4 (33.33)24.3611
2020's3 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.85 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]